Medical guideline

首页肿瘤学指南检索结果

检索结果

按发表年份

共搜索到16条与survival有关的结果

Brazilian Group of Gastrointestinal Tumours' Consensus Guidelines for the Management of Oesophageal Cancer

2021年发布于 ecancermedicalscience 127卷第4期 所属人体系统：消化 | 胃肠道肿瘤

Brazilian Group of Gastrointestinal Tumours'

Adult aplastic Anemia article cancer Patient cord Blood Stem Cell Transplantation disease Free Survival drug Therapy graft Recipient hematologic Malignancy human patient Selection practice Guideline surgery thymocyte Antibody
指南简介 原文链接
Colorectal Cancer

2020年发布于 National Institute for Health and Care Excellence 卷第期 所属人体系统：消化 | 结直肠肿瘤

National Institute for Health and Care Excellence

Colorectal Cancer QOL survival management
指南简介 原文链接
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

2020年发布于 Eur Urol 77卷第4期 所属人体系统：生殖 | 前列腺肿瘤

Advanced Prostate Cancer Consensus Conference 2019

Advanced Prostate Cancer Castration-naïve Prostate Cancer Castration-resistant Prostate Cancer Genetics High-risk Localised Prostate Cancer Hormone-sensitive Prostate Cancer Imaging Oligometastatic Prostate Cancer Overall Survival Progression-free Survival Prostate Cancer Treatment Tumour Genomic Profiling
指南简介 原文链接
French CcAFU Guidelines - Update 2020-2022: Bladder Cancer

2020年发布于 Prog Urol 30卷第12S期 所属人体系统：泌尿 | 膀胱肿瘤

Cancer Committee of the Association Française D'Urologie

BCG Bladder Bladder Neoplams Cancer Cystectomie Cystectomy Cytologie Urinaire Cytology Medical Subject Headings (MeSH) Carcinome Urothélial Medical Subject Headings (MeSH) Urothelial Carcinoma Survie Survival Tumeurs De La Vessie Vessie.
指南简介 原文链接
Consensus on the Use of Immune-related Response Criteria to Evaluate the Efficacy of Immunotherapy in Non-small Cell Lung Cancer

2019年发布于 Clinical and Translational Oncology 21卷第11期 所属人体系统：呼吸 | 肺癌

无

Immune Checkpoint Immunotherapy Overall Survival Response Criteria Consensus
指南简介 原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Short Text of the French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa

2019年发布于 Eur J Obstet Gynecol Reprod Biol 236卷第_期 所属人体系统：生殖 | 输卵管癌

FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN) Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF) La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)

An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (Grade A). in Presumed Early-stage Ovarian Or Tubal Cancers the Following Procedures Should Be Performed: an Omentectomy (at a Minimum Infracolic) an Appendectomy Multiple Peritoneal Biopsies Peritoneal Cytology (grade C) and Pelvic and Para-aortic Lymphadenectomies (Grade B) for All Histologic Types Except the Expansile Mucinous Subtypes for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer When There Is No Risk of Tumor Rupture (grade B). Adjuvant Chemotherapy by Carboplatin and Paclitaxel Is Recommended for All High-grade Ovarian and Tubal Cancers (FIGO Stages I-IIA) (grade A). for FIGO Stage III Or IV Ovarian Tubal and Primary Peritoneal Cancers a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (Grade B) as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e. Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian Tubal Or Primary Peritoneal Cancers (grade B). for Advanced Cancers Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B). after Primary Surgery Is Complete 6 Cycles of Intravenous Chemotherapy (grade A) Are Recommended Or a Discussion with the Patient About Intraperitoneal Chemotherapy According to Her Risk-benefit Ratio. after Complete Interval Surgery for FIGO Stage III Disease Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Can Be Proposed in Accordance with the Modalities of the OV-HIPEC Trial (grade B). in Cases of Postoperative Tumor Residue Or in FIGO Stage IV Tumors Chemotherapy Associated with Bevacizumab Is Recommended (grade A).
指南简介 原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Long Text of the Joint French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa. Part 1: Diagnostic Exploration and Staging, Surgery, Perioperative Care, and Pathology

2019年发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷第6期 所属人体系统：生殖 | 输卵管癌

FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN) Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF) La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)

An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (grade A). in Presumed Early-stage Ovarian Or Tubal Cancers the Following Procedures Should Be Performed: an Omentectomy (at a Minimum Infracolic) an Appendectomy Multiple Peritoneal Biopsies Peritoneal Cytology (grade C) and Pelvic and Para-aortic Lymphadenectomies (grade B) for All Histologic Types Except the Expansile Mucinous Subtypes for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer When There Is No Risk of Tumor Rupture (grade B). for FIGO Stages III Or IV Ovarian Tubal and Primary Peritoneal Cancers a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (grade B) as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e. Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian Tubal Or Primary Peritoneal Cancer (grade B). for Advanced Cancers Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B).
指南简介 原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Short Text of the French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa

2019年发布于 Eur J Obstet Gynecol Reprod Biol 236卷第_期 所属人体系统：生殖 | 卵巢肿瘤

FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN) Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF) La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)

An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (Grade A). in Presumed Early-stage Ovarian Or Tubal Cancers the Following Procedures Should Be Performed: an Omentectomy (at a Minimum Infracolic) an Appendectomy Multiple Peritoneal Biopsies Peritoneal Cytology (grade C) and Pelvic and Para-aortic Lymphadenectomies (Grade B) for All Histologic Types Except the Expansile Mucinous Subtypes for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer When There Is No Risk of Tumor Rupture (grade B). Adjuvant Chemotherapy by Carboplatin and Paclitaxel Is Recommended for All High-grade Ovarian and Tubal Cancers (FIGO Stages I-IIA) (grade A). for FIGO Stage III Or IV Ovarian Tubal and Primary Peritoneal Cancers a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (Grade B) as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e. Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian Tubal Or Primary Peritoneal Cancers (grade B). for Advanced Cancers Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B). after Primary Surgery Is Complete 6 Cycles of Intravenous Chemotherapy (grade A) Are Recommended Or a Discussion with the Patient About Intraperitoneal Chemotherapy According to Her Risk-benefit Ratio. after Complete Interval Surgery for FIGO Stage III Disease Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Can Be Proposed in Accordance with the Modalities of the OV-HIPEC Trial (grade B). in Cases of Postoperative Tumor Residue Or in FIGO Stage IV Tumors Chemotherapy Associated with Bevacizumab Is Recommended (grade A).
指南简介 原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Long Text of the Joint French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa. Part 1: Diagnostic Exploration and Staging, Surgery, Perioperative Care, and Pathology

2019年发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷第6期 所属人体系统：生殖 | 卵巢肿瘤

FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN) Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF) La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)

An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (grade A). in Presumed Early-stage Ovarian Or Tubal Cancers the Following Procedures Should Be Performed: an Omentectomy (at a Minimum Infracolic) an Appendectomy Multiple Peritoneal Biopsies Peritoneal Cytology (grade C) and Pelvic and Para-aortic Lymphadenectomies (grade B) for All Histologic Types Except the Expansile Mucinous Subtypes for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer When There Is No Risk of Tumor Rupture (grade B). for FIGO Stages III Or IV Ovarian Tubal and Primary Peritoneal Cancers a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (grade B) as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e. Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian Tubal Or Primary Peritoneal Cancer (grade B). for Advanced Cancers Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B).
指南简介 原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Short Text of the French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa

2019年发布于 Eur J Obstet Gynecol Reprod Biol 236卷第_期 所属人体系统：其他 | 腹膜肿瘤

FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN) Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF) La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)

An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (Grade A). in Presumed Early-stage Ovarian Or Tubal Cancers the Following Procedures Should Be Performed: an Omentectomy (at a Minimum Infracolic) an Appendectomy Multiple Peritoneal Biopsies Peritoneal Cytology (grade C) and Pelvic and Para-aortic Lymphadenectomies (Grade B) for All Histologic Types Except the Expansile Mucinous Subtypes for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer When There Is No Risk of Tumor Rupture (grade B). Adjuvant Chemotherapy by Carboplatin and Paclitaxel Is Recommended for All High-grade Ovarian and Tubal Cancers (FIGO Stages I-IIA) (grade A). for FIGO Stage III Or IV Ovarian Tubal and Primary Peritoneal Cancers a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (Grade B) as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e. Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian Tubal Or Primary Peritoneal Cancers (grade B). for Advanced Cancers Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B). after Primary Surgery Is Complete 6 Cycles of Intravenous Chemotherapy (grade A) Are Recommended Or a Discussion with the Patient About Intraperitoneal Chemotherapy According to Her Risk-benefit Ratio. after Complete Interval Surgery for FIGO Stage III Disease Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Can Be Proposed in Accordance with the Modalities of the OV-HIPEC Trial (grade B). in Cases of Postoperative Tumor Residue Or in FIGO Stage IV Tumors Chemotherapy Associated with Bevacizumab Is Recommended (grade A).
指南简介 原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Long Text of the Joint French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa. Part 1: Diagnostic Exploration and Staging, Surgery, Perioperative Care, and Pathology

2019年发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷第6期 所属人体系统：其他 | 腹膜肿瘤

FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN) Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF) La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)

An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (grade A). in Presumed Early-stage Ovarian Or Tubal Cancers the Following Procedures Should Be Performed: an Omentectomy (at a Minimum Infracolic) an Appendectomy Multiple Peritoneal Biopsies Peritoneal Cytology (grade C) and Pelvic and Para-aortic Lymphadenectomies (grade B) for All Histologic Types Except the Expansile Mucinous Subtypes for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer When There Is No Risk of Tumor Rupture (grade B). for FIGO Stages III Or IV Ovarian Tubal and Primary Peritoneal Cancers a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (grade B) as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e. Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian Tubal Or Primary Peritoneal Cancer (grade B). for Advanced Cancers Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B).
指南简介 原文链接
French CcAFU Guidelines - Update 2018-2020: Bladder Cancer

2018年发布于 Prog Urol 20卷第28(S1)期 所属人体系统：泌尿 | 膀胱肿瘤

Françaises Du Comité De Cancérologie De L’AFU

Urothelial Carcinoma Bladder Cytology Bladder Neoplams Cancer BCG Cystectomy Survival
指南简介 原文链接
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update

2018年发布于 Eur Urol 73卷第1期 所属人体系统：泌尿 | 尿路上皮癌

European Association of Urology

Cytology Guidelines Nephroureterectomy Renal Pelvis Risk Factors Survival Ureter Ureteroscopy Urinary Tract Cancer Urothelial Carcinoma
指南简介 原文链接
ACOG Committee Opinion No. 747 Summary: Gynecologic Issues in Children and Adolescent Cancer Patients and Survivors

2018年发布于 Obstet Gynecol 132卷第2期 所属人体系统：其他 | 儿童/青少年肿瘤

American College of Obstetricians and Gynecologists

Cancer Cancer Therapy Childhood Cancer Survival
指南简介 原文链接
SEOM Clinical Guideline in Nasopharynx Cancer (2017)

2018年发布于 Clin Transl Oncol 20卷第1期 所属人体系统：呼吸 | 鼻咽癌

Spanish Society of Medical Oncology

Nasopharyngeal Carcinoma survival Time
指南简介 原文链接
EANM Guideline for Radionuclide Therapy with Radium-223 of Metastatic Castration-resistant Prostate Cancer

2018年发布于 Eur J Nucl Med Mol Imaging 45卷第5期 所属人体系统：生殖 | 前列腺肿瘤

Eanm - European Association of Nuclear Medicine

Alpha Emitters Bone Metastases Prostate Cancer Radionuclide Therapy Radium-223 Survival Benefit
指南简介 原文链接

人体系统

共搜索到16条 与survival有关的结果

2021年 发布于 ecancermedicalscience 127卷 第4期 所属人体系统： 消化 | 胃肠道肿瘤

Brazilian Group of Gastrointestinal Tumours'

2020年 发布于 National Institute for Health and Care Excellence 卷 第期 所属人体系统： 消化 | 结直肠肿瘤

National Institute for Health and Care Excellence

2020年 发布于 Eur Urol 77卷 第4期 所属人体系统： 生殖 | 前列腺肿瘤

Advanced Prostate Cancer Consensus Conference 2019

2020年 发布于 Prog Urol 30卷 第12S期 所属人体系统： 泌尿 | 膀胱肿瘤

Cancer Committee of the Association Française D'Urologie

2019年 发布于 Clinical and Translational Oncology 21卷 第11期 所属人体系统： 呼吸 | 肺癌

无

2019年 发布于 Eur J Obstet Gynecol Reprod Biol 236卷 第_期 所属人体系统： 生殖 | 输卵管癌

2019年 发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷 第6期 所属人体系统： 生殖 | 输卵管癌

2019年 发布于 Eur J Obstet Gynecol Reprod Biol 236卷 第_期 所属人体系统： 生殖 | 卵巢肿瘤

2019年 发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷 第6期 所属人体系统： 生殖 | 卵巢肿瘤

2019年 发布于 Eur J Obstet Gynecol Reprod Biol 236卷 第_期 所属人体系统： 其他 | 腹膜肿瘤

2019年 发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷 第6期 所属人体系统： 其他 | 腹膜肿瘤

2018年 发布于 Prog Urol 20卷 第28(S1)期 所属人体系统： 泌尿 | 膀胱肿瘤

Françaises Du Comité De Cancérologie De L’AFU

2018年 发布于 Eur Urol 73卷 第1期 所属人体系统： 泌尿 | 尿路上皮癌

European Association of Urology

2018年 发布于 Obstet Gynecol 132卷 第2期 所属人体系统： 其他 | 儿童/青少年肿瘤

American College of Obstetricians and Gynecologists

2018年 发布于 Clin Transl Oncol 20卷 第1期 所属人体系统： 呼吸 | 鼻咽癌

Spanish Society of Medical Oncology

2018年 发布于 Eur J Nucl Med Mol Imaging 45卷 第5期 所属人体系统： 生殖 | 前列腺肿瘤

Eanm - European Association of Nuclear Medicine

共搜索到16条与survival有关的结果

2021年发布于 ecancermedicalscience 127卷第4期 所属人体系统：消化 | 胃肠道肿瘤

2020年发布于 National Institute for Health and Care Excellence 卷第期 所属人体系统：消化 | 结直肠肿瘤

2020年发布于 Eur Urol 77卷第4期 所属人体系统：生殖 | 前列腺肿瘤

2020年发布于 Prog Urol 30卷第12S期 所属人体系统：泌尿 | 膀胱肿瘤

2019年发布于 Clinical and Translational Oncology 21卷第11期 所属人体系统：呼吸 | 肺癌

2019年发布于 Eur J Obstet Gynecol Reprod Biol 236卷第_期 所属人体系统：生殖 | 输卵管癌

2019年发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷第6期 所属人体系统：生殖 | 输卵管癌

2019年发布于 Eur J Obstet Gynecol Reprod Biol 236卷第_期 所属人体系统：生殖 | 卵巢肿瘤

2019年发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷第6期 所属人体系统：生殖 | 卵巢肿瘤

2019年发布于 Eur J Obstet Gynecol Reprod Biol 236卷第_期 所属人体系统：其他 | 腹膜肿瘤

2019年发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷第6期 所属人体系统：其他 | 腹膜肿瘤

2018年发布于 Prog Urol 20卷第28(S1)期 所属人体系统：泌尿 | 膀胱肿瘤

2018年发布于 Eur Urol 73卷第1期 所属人体系统：泌尿 | 尿路上皮癌

2018年发布于 Obstet Gynecol 132卷第2期 所属人体系统：其他 | 儿童/青少年肿瘤

2018年发布于 Clin Transl Oncol 20卷第1期 所属人体系统：呼吸 | 鼻咽癌

2018年发布于 Eur J Nucl Med Mol Imaging 45卷第5期 所属人体系统：生殖 | 前列腺肿瘤